Medcognetics
- Company typePrivate
- Founded2020
- HeadquartersDallas, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Medcognetics firmographics
Firmographics- Name
- Medcognetics
- Legal name
- MedCognetics, Inc.
- Website
- https://medcognetics.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Medcognetics industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC)
- akta.pro secondary industry
- Mammography & Breast Imaging Systems (HLAHABAF)
Keywords
Where Medcognetics is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Medcognetics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- AI Software Licenses/Subscriptions: MedCognetics generates revenue through licensing its FDA-cleared AI software (CogNet AI-MT, CogNet AI-MT+) to healthcare institutions including hospitals and imaging centers. The company offers cloud-based, on-premises, and embedded deployment options, suggesting subscription or license-based pricing models for its AI products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise licensing with flexible deployment options |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Medcognetics product offering
Product offeringCore offering
MedCognetics develops and licenses AI-powered medical imaging software for breast cancer and lung disease detection. Its core CogNet platform provides FDA-cleared computer-aided triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis for mammography, as well as chest X-ray and low-dose CT analysis for lung screening. The software is offered via cloud, on-premises, embedded, and web portal deployment to hospitals, imaging centers, and global health programs.
Product overview
Medcognetics offers a unified AI platform with multiple product lines. The core CogNet Mammo suite (built on US patents 11,948,297 B1 and 12,243,232 B1) provides breast cancer screening AI including triage (CogNet AI-MT/AI-MT+), detection, density assessment, patient risk scoring, and breast arterial calcification analysis. CogNet Lung extends AI capabilities to chest X-ray and low-dose CT for lung disease detection. The platform supports Flexible Deployment options (cloud, on-premises, embedded, web portal) and includes Proprietary Tools for AI development. CogNet AI-MT received FDA 510(k) clearance in December 2022, with CogNet AI-MT+ receiving FDA clearance in February 2026 for DBT triage.
Differentiator
Problem solved
Functional benefit
Brands
- CogNet Mammo: AI suite for breast cancer screening and women's health outcomes, including triage, detection, density assessment, patient risk scoring, and breast arterial calcification analysis.
- CogNet Lung
- CogNet AI-MT
- CogNet AI-MT+
- Proprietary Tools
Products and services
- CogNet Mammo Comprehensive AI suite for breast cancer screening and women's health, including triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis. Built on two foundational U.S. patents for unbiased mammogram analysis. Targets hospitals, imaging centers, and global health programs.
- CogNet AI-MT+ FDA 510(k) cleared AI-enabled radiological computer-aided triage and notification software for breast imaging. Flags suspicious 3D mammography (DBT) exams for prioritized radiologist review, helping manage increasing imaging volumes.
- CogNet AI-MT FDA-cleared AI platform for triage of mammogram images in the cloud. Analyzes screening mammograms and flags exams suggestive of suspicious findings for worklist prioritization and workflow optimization.
- CogNet Lung Suite of AI products for lung cancer screening and disease detection, including chest X-ray and low-dose CT analysis for abnormality detection, nodule identification, and lung disease screening.
- Embedded AI Embedded AI image processing and cancer detection system combining medical-grade edge AI hardware with CogNet AI-MT software, enabling on-premises deployment with real-time results, enhanced image quality (denoising, microcalcification enhancement, motion suppression), and workflow optimization directly in the imaging device.
- Proprietary Tools End-to-end AI development platform including synthetic data generation, generative AI-powered data curation, an evaluation framework for subgroup-specific performance testing, data annotation tools, and foundation models for breast and lung imaging. Sold as a standalone offering for AI development and validation.
Quantifiable outcome
- Reduces diagnostic review time and enables radiologists to prioritize suspicious mammograms
- +1 more outcomes
Companies that use Medcognetics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Medcognetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature10 records
Medcognetics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship and core.
- Health Within Reach Foundation (HWRF)flagshipPartnership with Pune-based nonprofit HWRF to deploy AI-enabled mobile mammography units across India. The initiative brings screening directly to underserved and remote rural communities, using edge-based deployment for real-time image processing in areas with limited connectivity.
- Laurel Bridge SoftwarecoreCollaboration to develop integrated AI workflow and security solutions for breast cancer screening and diagnosis. The partnership aims to improve clinical efficiency, data security, and patient outcomes while supporting FDA standards for trustworthy AI in healthcare.
- University of Texas at DallascoreAcademic research partnership with UT Dallas, where the company was co-founded. Lakshman Tamil serves as Co-founder and Professor at UT Dallas. The partnership supports ongoing AI research and development for medical imaging.
- University of Texas Southwestern Medical CentercoreResearch collaboration with UTSW for AI development and validation in medical imaging. Part of Dallas-based healthcare ecosystem.
- AWS Partner NetworkcoreMedCognetics is a member of the AWS Partner Network, enabling cloud-based deployment of FDA-cleared AI solutions through secure, HIPAA-compliant AWS infrastructure.
- NM Medical, Mumbai, IndiacoreClinical deployment partnership with NM Medical in Mumbai, India. Dr. Shilpa Lad serves as radiologist advisor. Has screened thousands of patients across diverse ethnic demographics.
- AKARUI SolutionscorePartnership with AKARUI Solutions to deploy MedCognetics' AI imaging platform for expanding breast cancer screening access in rural India.
- Four Nigerian University HospitalscoreDeployment of unbiased AI platform in four Nigerian university hospitals, screening thousands of patients across diverse ethnic demographics as part of the company's global health initiative.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Medcognetics competitors and assessment
Company assessmentBroad incumbents
- Aidoc: Broad radiology AI platform with FDA-cleared algorithms across multiple modalities including chest CT, sold to large hospital systems—an incumbent MedCognetics competes against when extending into lung.
- Hologic: Mammography equipment OEM (Selenia Dimensions / 3Dimensions) that bundles its own Genius AI for DBT. Competes both at the device level and the AI-software layer MedCognetics targets.
Direct peers
- Riverain Technologies (ClearRead): Provides ClearRead CT and ClearRead XR AI tools for chest imaging, directly comparable to MedCognetics' CogNet Lung suite for lung cancer screening and chest X-ray analysis.
- CureMetrix: Developer of cmTriage and cmAngio AI for mammography workflow and cancer detection, focused on the same hospital and imaging-center customer segment.
- Therapixel: French AI vendor with MammoScreen 2.0 for mammography triage and detection, an FDA-cleared competitor to MedCognetics' CogNet AI-MT+ in the U.S. market.
- Lunit: Korean AI company with INSIGHT MMG and INSIGHT DBT for mammography triage and detection, plus INSIGHT CXR for chest X-ray—directly overlapping MedCognetics' breast and lung AI roadmap and global commercial footprint.
- iCAD, Inc. Mammography AI vendor behind ProFound AI for DBT and 2D mammography, with FDA-cleared triage, detection, and risk products serving U.S. hospitals and imaging centers in the same customer base.
- Volpara Health Technologies: Provides AI-powered breast imaging analytics including density assessment and risk scoring (Volpara Scorecard), sold to the same hospital and imaging-center customers MedCognetics targets.
- ScreenPoint Medical: Developer of Transpara, an FDA-cleared AI decision-support tool for mammography (2D and DBT) used in U.S. and European screening programs—directly comparable to CogNet AI-MT/AI-MT+.
- DeepHealth (RadNet): RadNet-owned AI subsidiary offering Saige-Dx for mammography decision support and a broader radiology AI portfolio, with deep U.S. imaging-center distribution.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Medcognetics social profiles
Digital presenceMedcognetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medcognetics leadership team
Management profileNumber of profiles
Profiles7 records
Medcognetics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medcognetics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medcognetics
What does Medcognetics do?
MedCognetics develops and licenses AI-powered medical imaging software for breast cancer and lung disease detection. Its core CogNet platform provides FDA-cleared computer-aided triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis for mammography, as well as chest X-ray and low-dose CT analysis for lung screening. The software is offered via cloud, on-premises, embedded, and web portal deployment to hospitals, imaging centers, and global health programs.
Is Medcognetics a public or private company?
Medcognetics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medcognetics founded?
Medcognetics was founded in 2020. It employs 1 to 10 people.
Where is Medcognetics based?
Medcognetics is headquartered in Dallas, United States, in the North America region.
How does Medcognetics make money?
One revenue line is on record: AI Software Licenses/Subscriptions.
Who are Medcognetics's main competitors?
Broad incumbents on record are Aidoc and Hologic. Direct peers are Riverain Technologies (ClearRead), CureMetrix, Therapixel, Lunit, iCAD, Inc., Volpara Health Technologies, ScreenPoint Medical and DeepHealth (RadNet).
Does Medcognetics have an API?
No public API is recorded for Medcognetics.
What industry is Medcognetics in?
Medcognetics's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories, with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 339112 and its SIC code is 3841.